Related Experiment Video
Updated: Aug 11, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Detection of BCR-ABL mutations and resistance to imatinib mesylate
Susan Branford1, Timothy Hughes
1Division of Molecular Pathology, Institute of Medical and Veterinary Science, South Australia.
Abstract:
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase activity. The early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance. Direct sequencing of the BCR-ABL kinase domain is relatively rapid and allows detection of emerging mutations at a sensitivity of approx 20%. Mutations have been detected over a range of 242 amino acids, which spans the entire kinase domain. For optimal sensitivity, the kinase domain of the abnormal gene should be isolated by reverse-transcription (RT) polymerase chain reaction (PCR) amplification using primers that hybridize to the BCR and ABL genes. The quality of the RNA is assessed by real-time quantitative PCR prior to analysis, and BCR-ABL levels are determined. Only RNA of adequate quality is used to ensure accurate and reproducible mutation analysis. Depending on the level of BCR-ABL transcripts, a one- or two-step PCR is required to amplify the kinase domain. Direct sequencing with dye terminator chemistry is performed using PCR-purified products. The sequence is compared to an ABL kinase domain reference sequence using sequencing analysis software, which aligns the sequences and highlights single or multiple mutations.
Insights
Detecting mutations in the Bcr-Abl fusion tyrosine kinase is key to overcoming imatinib resistance in chronic myeloid leukemia (CML). Early detection via direct sequencing of the BCR-ABL kinase domain enables timely treatment adjustments for CML patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Imatinib resistance in chronic myeloid leukemia (CML) is primarily driven by mutations in the Bcr-Abl fusion tyrosine kinase.
- These mutations decrease imatinib's efficacy, leading to treatment failure.
- Early identification of these resistance mutations is crucial for effective CML management.
Purpose of the Study:
- To establish a sensitive and rapid method for detecting Bcr-Abl kinase domain mutations.
- To enable early intervention strategies for CML patients developing imatinib resistance.
- To analyze the full 242 amino acid range of the kinase domain for mutations.
Main Methods:
- RNA isolation and quality assessment using real-time quantitative PCR.
- Reverse-transcription polymerase chain reaction (RT-PCR) amplification of the BCR-ABL kinase domain.
- Direct sequencing of amplified products using dye terminator chemistry and comparative analysis with reference sequences.
Main Results:
- Direct sequencing can detect emerging mutations with approximately 20% sensitivity.
- Mutations were identified across the entire 242 amino acid kinase domain.
- RT-PCR amplification is essential for isolating the target gene for mutation analysis.
Conclusions:
- Direct sequencing of the BCR-ABL kinase domain is a viable method for detecting imatinib resistance mutations in CML.
- Accurate RNA quality assessment and optimized PCR are critical for reliable mutation detection.
- This approach facilitates timely treatment adjustments, potentially overcoming imatinib resistance in CML patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...